Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
J Remon, C Caramella, C Jovelet, et al.
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2019
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Y-L Wu, D Planchard, S Lu, et al.
Journal of Crohn'S & Colitis
|
January 20, 2016
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L Marthey, C Mateus, C Mussini, et al.
ESMO Open
|
April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
J Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, J C-H Yang, K Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
J Chen, F Facchinetti, F Braye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
J Remon, C Caramella, C Jovelet, et al.
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2019
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Y-L Wu, D Planchard, S Lu, et al.
Journal of Crohn'S & Colitis
|
January 20, 2016
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L Marthey, C Mateus, C Mussini, et al.
ESMO Open
|
April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
J Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, J C-H Yang, K Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
J Chen, F Facchinetti, F Braye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, et al.
Page
of 6